Who owns ACUMEN PHARMACEUTICALS INC?
- Ticker: ABOS
- CUSIP Number: 00509g209
Tip: Access positions for across all investors
Analyze quarterly positions in Acumen Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Acumen Pharmaceuticals stock
Who bought or sold ACUMEN PHARMACEUTICALS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 15M | $61M | 0% | Mar 2024 |
|
| Sands Capital Ventures | 3.4M | $14M | 0% | Mar 2024 |
|
| Franklin Resources | 3.4M | $14M | 1% | Mar 2024 |
|
| Millennium Management | 2.6M | $11M | 76% | Mar 2024 |
|
| Rock Springs Capital Management | 2.3M | $9.3M | -18% | Mar 2024 |
|
| FMR | 2.1M | $8.5M | 317860% | Mar 2024 |
|
| Laurion Capital Management | 1.9M | $7.7M | 0% | Mar 2024 |
|
| Vanguard Group | 1.7M | $6.7M | -9% | Mar 2024 |
|
| T. Rowe Price Associates | 1.1M | $4.4M | 100% | Mar 2024 |
|
| Alyeska Investment Group | 940k | $3.8M | 28% | Mar 2024 |
|
| Jane Street | 600k | $2.4M | -1% | Mar 2024 |
|
| Susquehanna International | 584k | $2.4M | 22% | Mar 2024 |
|
| Parkman Healthcare Partners | 577k | $2.3M | 15% | Mar 2024 |
|
| Hudson Bay Capital Management | 560k | $2.3M | -1% | Mar 2024 |
|
| Pathstone Holdings | 480k | $1.9M | 0% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 459k | $1.9M | -18% | Mar 2024 |
|
| Goldman Sachs Group | 318k | $1.3M | 177% | Mar 2024 |
|
| Geode Capital Management | 285k | $1.2M | 8% | Mar 2024 |
|
| Ikarian Capital | 266k | $1.1M | -15% | Mar 2024 |
|
| Tang Capital Management | 247k | $1000k | 0% | Mar 2024 |
|
| Two Sigma Advisers | 217k | $879k | 67% | Mar 2024 |
|
| BlackRock | 190k | $768k | -67% | Mar 2024 |
|
| Man Group | 188k | $760k | 30% | Mar 2024 |
|
| Two Sigma Investments | 178k | $721k | -27% | Mar 2024 |
|
| Qube Research & Technologies | 168k | $679k | 542% | Mar 2024 |
|
| TD Asset Management | 149k | $603k | 100% | Mar 2024 |
|
| Bridgeway Capital Management | 148k | $601k | 29% | Mar 2024 |
|
| Citigroup | 135k | $548k | -8% | Mar 2024 |
|
| Squarepoint Ops | 113k | $459k | 114% | Mar 2024 |
|
| Hrt Financial | 105k | $425k | 100% | Mar 2024 |
|
| Jump Financial | 103k | $396k | 204% | Dec 2023 |
|
| New York Life Investment Management | 95k | $385k | 100% | Mar 2024 |
|
| Marshall Wace | 90k | $363k | 100% | Mar 2024 |
|
| Catalyst Financial Partners | 90k | $311k | 0% | Mar 2024 |
|
| Bank of America Corporation | 81k | $327k | -23% | Mar 2024 |
|
| Caption Management | 75k | $304k | -38% | Mar 2024 |
|
| Jpmorgan Chase & Co | 72k | $291k | 112% | Mar 2024 |
|
| Balyasny Asset Management | 64k | $259k | 211% | Mar 2024 |
|
| Susquehanna Fundamental Investments | 63k | $253k | 100% | Mar 2024 |
|
| Dimensional Fund Advisors | 62k | $250k | 11% | Mar 2024 |
|
| Marathon Trading Investment Management | 60k | $243k | 100% | Mar 2024 |
|
| Northern Trust | 57k | $230k | 1% | Mar 2024 |
|
| Brevan Howard Capital Management | 56k | $228k | 100% | Mar 2024 |
|
| Boothbay Fund Management | 52k | $209k | -15% | Mar 2024 |
|
| Morgan Stanley | 49k | $197k | 119% | Mar 2024 |
|
| Barclays | 47k | $190k | 0% | Mar 2024 |
|
| Y-Intercept | 37k | $151k | 100% | Mar 2024 |
|
| Springbok Capital Management | 37k | $150k | 100% | Mar 2024 |
|
| Citadel Advisors | 35k | $141k | -76% | Mar 2024 |
|
| American Century Companies | 35k | $140k | 150% | Mar 2024 |
|
| Bank Of Montreal | 32k | $132k | 100% | Mar 2024 |
|
| Intrepid Financial Planning Group | 30k | $122k | 0% | Mar 2024 |
|
| Group One Trading | 28k | $114k | 100% | Mar 2024 |
|
| Point72 Asia | 28k | $112k | 1278% | Mar 2024 |
|
| ExodusPoint Capital Management | 26k | $104k | 100% | Mar 2024 |
|
| GSA Capital Partners | 25k | $103k | 100% | Mar 2024 |
|
| Susquehanna Portfolio Strategies | 22k | $89k | 100% | Mar 2024 |
|
| Leucadia National Corporation | 19k | $77k | 100% | Mar 2024 |
|
| Gail Mannix | 18k | $73k | 100% | Mar 2024 |
|
| Pinnacle Wealth Management Advisory | 18k | $73k | 100% | Mar 2024 |
|
| Stifel Financial | 15k | $59k | -9% | Mar 2024 |
|
| Chicago Partners Investment | 14k | $44k | -24% | Mar 2024 |
|
| SG Americas Securities | 13k | $52k | 100% | Mar 2024 |
|
| LMR Partners | 12k | $47k | 100% | Mar 2024 |
|
| CTC Alternative Strategies | 11k | $45k | 100% | Mar 2024 |
|
| Advisor Group Holdings | 10k | $42k | 2500% | Mar 2024 |
|
| Integrated Wealth Concepts | 10k | $41k | -26% | Mar 2024 |
|
| UBS Group | 6.6k | $27k | 82938% | Mar 2024 |
|
| Cubist Systematic Strategies | 2.4k | $9.7k | -93% | Mar 2024 |
|
| Sandy Spring Bank | 1.5k | $6.1k | 100% | Mar 2024 |
|
| Tower Research Capital | 1.4k | $5.7k | -34% | Mar 2024 |
|
| Wells Fargo & Company | 1.2k | $4.9k | -45% | Mar 2024 |
|
| Royal Bank of Canada | 102.00 | $0 | -85% | Mar 2024 |
|
Who sold out of Acumen Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Altium Capital Management | Sep 2023 | 650k | $2.7M |
| D. E. Shaw & Co | Dec 2023 | 138k | $530k |
| Wellington Management Company | Sep 2023 | 104k | $433k |
| 683 Capital Management | Dec 2023 | 78k | $301k |
| Virtu Financial | Dec 2023 | 24k | $91k |
| Verition Fund Management | Sep 2023 | 24k | $98k |
| Simplex Trading | Dec 2023 | 21k | $82k |
| Occudo Quantitative Strategies | Dec 2023 | 17k | $65k |
| XTX Topco | Sep 2023 | 17k | $69k |
| Global Retirement Partners | Dec 2023 | 2.0k | $7.3k |
| Cutler | Dec 2023 | 1.2k | $4.0k |
| Advisory Services Network | Dec 2023 | 1.0k | $3.8k |
| Zurcher Kantonalbank | Dec 2023 | 413.00 | $1.6k |